Table ​Table11 provides a review on the clinical trials carried out on the usage of MDMA in the management of PTSD. Inside the ketamine group, 67% of patients realized treatment response, described as at least a 30% reduction in PTSD symptom severity on the CAPS-5 from baseline to 2 months, https://menachemc814iil7.wikidirective.com/user